Volume 4.23 | Jun 14

Mammary Cell News 4.23 June 14, 2012
Mammary Cell News
     In this issue: Publications | Science News | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook  Mammary Cell News on Twitter
Profiling of Residual Breast Cancers after Neoadjuvant Chemotherapy Identifies DUSP4 Deficiency as a Mechanism of Drug Resistance
Researchers found dual specificity protein phosphatase 4 (DUSP4) downregulation activates the Ras-ERK pathway in basal-like breast cancer, resulting in an attenuated response to anti-cancer chemotherapy. [Nat Med] Abstract | Press Release | Video

View Lectures, Tools, Protocols and Other Resources on the Human Immunology Portal (www.humanimmunologyportal.com)
PUBLICATIONS (Ranked by impact factor of the journal)


p53-Mediated Senescence Impairs the Apoptotic Response to Chemotherapy and Clinical Outcome in Breast Cancer
Scientists showed that wild-type p53 activity hinders chemotherapy response and demonstrated the need to reassess the paradigm for p53 in cancer therapy. [Cancer Cell] Abstract | Press Release

Implanted Adipose Progenitor Cells as Physicochemical Regulators of Breast Cancer
Through the integration of physical sciences and oncology approaches, researchers investigated the capability of tumor-derived chemical and mechanical cues to enhance adipose-derived stem cell-mediated contributions to tumor stroma formation. [Proc Natl Acad Sci USA] Abstract

MicroRNA93 Regulates Proliferation and Differentiation of Normal and Malignant Breast Stem Cells
Using a series of breast cancer cell lines representing different stages of differentiation and mouse xenograft models, scientists demonstrated that microRNA93 modulates the fate of breast cancer stem cells by regulating their proliferation and differentiation states. [PLoS Genet] Full Article

Overexpression of GOLPH3 Promotes Proliferation and Tumorigenicity in Breast Cancer via Suppression of the FOXO1 Transcription Factor
The role of golgi phosphoprotein 3 (GOLPH3) in breast cancer cell proliferation and tumorigenicity was explored in vitro and in vivo. [Clin Cancer Res] Abstract

MiR-21 Is Targeted by Omega-3 Polyunsaturated Fatty Acid to Regulate Breast Tumor CSF-1 Expression
Researchers reveal a novel mechanism for the therapeutic function of fish oil diet which blocks microRNA-21 (miR-21); thereby increasing PTEN levels to prevent expression of CSF-1 (colony stimulating factor-1) in breast cancer. [Carcinogenesis] Abstract

Targeting Facilitates Chromatin Transcription Complex Suppresses Mammary Tumorigenesis in Her2/Neu Transgenic Mice
Researchers tested whether Curaxin-137 could suppress tumorigenesis in MMTV-neu transgenic mice, which spontaneously develop mammary carcinoma due to steroid receptor-regulated expression of the Her2 proto-oncogene. [Cancer Prev Res] Abstract

CTGF Drives Autophagy, Glycolysis, and Senescence in Cancer Associated Fibroblasts via Hypoxia-Inducible Factor 1 Activation, Metabolically Promoting Tumor Growth
Investigators shed new light on the compartment-specific role of connective tissue growth factor (CTGF) in mammary tumorigenesis, and provide novel insights into the mechanism(s) generating a lethal tumor microenvironment in patients lacking stromal caveolin-1. [Cell Cycle] Abstract

A Targeted Enzyme Approach to Sensitization of Tyrosine Kinase Inhibitor-Resistant Breast Cancer Cells
Epidermal growth factor receptor (EGFR) has been shown to be overexpressed in breast cancer, and in particular remains hyperphosphorylated in cell lines such as MDA-MB-468 that are resistant to EGFR inhibitors. Researchers investigated the cause of this sustained phosphorylation and the molecular basis for the ineffectiveness of gefitinib. [Exp Cell Res] Abstract


Chemotherapy (CT) and Hormonotherapy (HT) as Neoadjuvant Treatment in Luminal Breast Cancer Patients: Results from the GEICAM/2006-03, a Multicenter, Randomized, Phase II Study
Scientists investigated the value of CT and HT in luminal breast cancer patients in the neoadjuvant setting. [Ann Oncol] Abstract

Mammaglobin-A cDNA Vaccination of Breast Cancer Patients Induces Antigen-Specific Cytotoxic CD4+ Inducible Co-Stimulatorhi T Cells
Researchers present results on a phase I clinical trial of a mammaglobin-A cDNA vaccination in breast cancer patients with stage-IV metastatic disease, including the impact of vaccination on the expression of the inducible co-stimulator molecule on CD4 T cells. [Breast Cancer Res Treat] Abstract

Randomized Phase II Study of Three Doses of Oral TAS-108 in Postmenopausal Patients with Metastatic Breast Cancer
This randomized phase II study was intended to identify the optimal dose of TAS-108, a novel steroidal antiestrogen, for the treatment of breast cancer in postmenopausal Japanese women. [Cancer Sci] Abstract

Listen Now: New Podcast on ALDH in Breast Cancer Treatment Response


For Some Breast Cancers, New Drug May Be Treatment Option
Results from an international clinical trial suggest that women with metastatic, HER2-positive breast cancer that is no longer responding to the targeted therapy trastuzumab may soon have a new treatment option. [Press release from the National Cancer Institute discussing research presented at the American Society of Clinical Oncology (ASCO) 2012 Annual Meeting, Chicago] Press Release

Even Low Doses of Radiation in Childhood May Raise Breast Cancer Risk
Dr. Chaya Moskowitz of Memorial Sloan-Kettering Cancer Center presented data from more than 1,200 women participating in the Childhood Cancer Survivor Study who received radiation to the chest as children, adolescents, or young adults. [Press release from the National Cancer Institute discussing research presented at the American Society of Clinical Oncology (ASCO) 2012 Annual Meeting, Chicago]
Press Release

Generex Announces Interviews Featuring the Antigen Express AE37 Breast Cancer Vaccine
Generex Biotechnology Corporation announced that two interviews were conducted featuring the on-going Phase II clinical trial of the Antigen Express AE37 immunotherapeutic breast cancer vaccine. [Press release from Generex Biotechnology Corporation discussing interviews conducted at the American Society of Clinical Oncology (ASCO) 2012 Annual Meeting, Chicago] Press Release | Video 1 | Video 2


Researcher Secures RO1 Grant from NCI/NIH to Study Role of Proteases in Breast Cancer
Karin List, Ph.D. has received a five year, $1,577,000 Research Project (RO1) Grant from the National Cancer Institute (NCI)/National Institutes of Health (NIH) to study the role of two proteases and their functions in breast cancer development and progression. [Wayne State University] Press Release

GE Healthcare and Affibody AB to Collaborate on Her2 Specific PET Imaging Agent for Breast and Gastric Cancer
GE Healthcare signed an agreement with Affibody AB to collaborate on the development of a Her2-targeted PET imaging agent, which is scheduled to begin clinical trials later this year. [Affibody AB] Press Release

TeSR™-E8™ and STEMdiff™: New Products to Advance Research on Human Pluripotent Stem Cells

STEMCELL Technologies Inc. announced its plans to release a series of new products to advance research and translational applications for human pluripotent stem cells. [STEMCELL Technologies Inc.]
Press Release


Pertuzumab Approved to Treat Some Metastatic Breast Cancers
The Food and Drug Administration has approved pertuzumab to treat women with HER2-positive breast cancer that has spread to other parts of the body. [National Cancer Institute, United States]
Press Release

National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)


NEW European Society for Medical Oncology (ESMO) 2012 Congress
September 28-October 2, 2012
Vienna, Austria

4th Annual United Arab Emirates (UAE) Cancer Congress 2012
October 11-13, 2012
Dubai, United Arab Emirates

Visit our events page to see a complete list of events in the mammary cell community.


Research Associate – Chemistry (STEMCELL Technologies, Inc.)

Research Associate – Particle Chemistry (STEMCELL Technologies, Inc.)

Research Technologist – Contract Assay Services (STEMCELL Technologies, Inc.)

Research Technologist – Media Development (STEMCELL Technologies, Inc.)

Scientist – Epithelial Cell Research (STEMCELL Technologies, Inc.)

Scientist – Induced Pluripotent Stem Cells (STEMCELL Technologies, Inc.)

Scientist – hPSC Bioengineering (STEMCELL Technologies Inc.)

Scientist – Mesenchymal Cell Research (STEMCELL Technologies, Inc.)

Business Analyst – Product Management (STEMSOFT Software Inc.)

Postdoctoral Position – Breast Cancer Research (Beckman Research Institute)

Postdoctoral Position – Gene Regulation in Breast Cancer/Stem Cell Biology (University of Cincinnati)

Research Fellowship – Transformed Signal Transduction Networks in Breast Cancer (Memorial Sloan-Kettering Cancer Center)

Recruit Top Talent: Reach more than 50,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Mammary Cell News? Click here to submit!

Comments or Suggestions? Email [email protected] with your feedback.

Learn more about Mammary Cell News: Archives | Events | Contact Us